Breast cancer drug will not be available on NHS
Summary of story from The Telegraph, November 10, 2011
The drug Faslodex, which may help women with breast cancer to live for a further three years, will not be provided by the UK’s National Health Service (NHS), following a ruling by the National Institute of Health and Clinical Excellence (Nice).
The drug costs £500 a month, up to 84 times more than alternatives already available, and the evidence it works any better is ‘uncertain’, a spokesman for Nice said.
Faslodex, also known as fulvestrant, is licensed to treat certain forms of breast cancer in older women who have already received some treatments.
It was to be used as an alternative to anastrozole and letrozole which are already in use in the NHS and are cheaper.
Data shows women on faslodex live for an average of 36 months, compared to 32 months for those on anastrozole and 31 months for those on letrozole.
Sir Andrew Dillon, Chief Executive of Nice, said: “While there is evidence that fulvestrant can delay the growth of breast cancer, our independent committee found that its effectiveness is uncertain compared to aromatise inhibitors, which are currently the preferred treatment options on the NHS.”
If no appeals are received by November 24, Nice hopes to publish final guidance for the NHS in January.
Maria Leadbeater, clinical nurse specialist at Breast Cancer Care, said the decision was ‘disappointing’.











